Literature DB >> 21486690

Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Martin Benesch1, Ivo Leuschner, Eva Wardelmann, Mareike Thielen, Irene Schmid, Udo Kontny, Georg Ebetsberger, Eva Frey, Norbert Graf, Dominik T Schneider, Bernhard Kremens, Gabriele Amann, Christian Urban, Marcus Schlemmer, Franz Quehenberger, Thomas Klingebiel, Tobias Dantonello, Ewa Koscielniak.   

Abstract

BACKGROUND: Studies on gastrointestinal stromal tumours (GIST) in the paediatric population are limited to case reports or small case series. PATIENTS AND METHODS: We conducted a retrospective study to describe the long-term outcome of children and adolescents with GIST registered in the database of the Cooperative Weichteilsarkom Studiengruppe (CWS).
RESULTS: Sixteen patients (female, n = 11) were identified. Median age at diagnosis was 13.5 years. In four female patients presence of thoracic masses in addition to GIST led to the diagnosis of complete or incomplete Carney triad. Three female patients had metastatic disease at diagnosis, the remaining thirteen GIST were localised. The stomach was the most common primary site of the tumour, followed by the small bowel and colon/abdomen. All patients underwent tumour resection. Receptor tyrosine kinase inhibitors (RTKI) were administered in five patients. With a median follow-up of 96 months all patients are alive, nine of them in first CR. Four female patients developed local or distant recurrence; three of them achieved second CR and one a PR. Two individuals have extensive progressive (n = 1) or stable (n = 1) disease. Estimated progression-free survival at 5 years is 0.63 (95%CI: 0.50-0.86).
CONCLUSIONS: Although long-term overall survival is favourable, approximately 30 percent of patients develop disease progression. International cooperation in registration, tissue collection and molecular studies are required to obtain reliable data on the clinical course of these rare tumours in the paediatric population. Biological studies are a prerequisite for initiation of studies with RTKI.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21486690     DOI: 10.1016/j.ejca.2011.03.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

Review 1.  Usual and unusual causes of pediatric gastric outlet obstruction.

Authors:  Jeffrey P Otjen; Ramesh S Iyer; Grace S Phillips; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2012-03-29

2.  Incidental GIST after appendectomy in a pediatric patient: a first instance and review of pediatric patients with CD117 confirmed GISTs.

Authors:  Sifrance Tran; Michael Dingeldein; Sarah C Mengshol; Saundra Kay; Anthony C Chin
Journal:  Pediatr Surg Int       Date:  2013-11-30       Impact factor: 1.827

3.  Inpatient burden of gastrointestinal stromal tumors in the United States.

Authors:  Manasi Datar; Rahul Khanna
Journal:  J Gastrointest Oncol       Date:  2012-12

4.  Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad.

Authors:  Claudia Otto; Abbas Agaimy; Alexander Braun; Jochen Rädecke; Jens Hoeppner; Gerald Illerhaus; Martin Werner; Udo Kontny; Florian Haller
Journal:  Diagn Pathol       Date:  2011-06-10       Impact factor: 2.644

5.  Mesenteric Leiomyoma in Infancy.

Authors:  Henrique Pavan; Marcos Frata Rihl; Sergio Luiz Oliveira de Freitas
Journal:  J Indian Assoc Pediatr Surg       Date:  2017 Jul-Sep

6.  Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.

Authors:  Arnauld C Verschuur; Viera Bajčiová; Leo Mascarenhas; Reza Khosravan; Xun Lin; Antonella Ingrosso; Katherine A Janeway
Journal:  Cancer Chemother Pharmacol       Date:  2019-04-20       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.